Short Interest in Immunic, Inc. (NASDAQ:IMUX) Rises By 22.7%

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,030,000 shares, a growth of 22.7% from the March 15th total of 2,470,000 shares. Based on an average daily volume of 976,400 shares, the short-interest ratio is presently 3.1 days.

Analysts Set New Price Targets

IMUX has been the subject of several research analyst reports. Brookline Capital Management reissued a "buy" rating and set a $10.00 price objective on shares of Immunic in a research report on Friday, April 5th. StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a research report on Friday, March 29th.

Hedge Funds Weigh In On Immunic

Several large investors have recently added to or reduced their stakes in IMUX. RTW Investments LP grew its stake in shares of Immunic by 0.9% in the 3rd quarter. RTW Investments LP now owns 4,335,255 shares of the company's stock valued at $6,373,000 after purchasing an additional 40,796 shares during the period. Acadian Asset Management LLC grew its stake in shares of Immunic by 26.8% in the 3rd quarter. Acadian Asset Management LLC now owns 757,250 shares of the company's stock valued at $1,111,000 after purchasing an additional 159,973 shares during the period. Sweet Financial Partners LLC bought a new stake in shares of Immunic in the 4th quarter valued at approximately $45,000. Innovis Asset Management LLC grew its stake in shares of Immunic by 46.3% in the 3rd quarter. Innovis Asset Management LLC now owns 272,457 shares of the company's stock valued at $401,000 after purchasing an additional 86,217 shares during the period. Finally, Marshall Wace LLP bought a new stake in shares of Immunic in the 3rd quarter valued at approximately $77,000. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Stock Down 9.0 %

Immunic stock traded down $0.13 during trading hours on Monday, hitting $1.31. The stock had a trading volume of 378,080 shares, compared to its average volume of 909,444. The company has a 50-day moving average of $1.33 and a two-hundred day moving average of $1.27. The company has a market cap of $117.81 million, a PE ratio of -0.62 and a beta of 2.07. Immunic has a fifty-two week low of $0.95 and a fifty-two week high of $3.11.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.03. As a group, analysts forecast that Immunic will post -0.99 EPS for the current fiscal year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.